CD40 and B-cell chronic lymphocytic leukemia: This indicates that aside from direct effects, continued treatment of ibrutinib leads to changes in the microenvironment that have indirect effects on CLL cells, highlighting the role of accessory cells mediating signaling via alternative receptors such as CD40 and TLRs.